Design And Development Of A Novel Formulation Of Pacritinib For Treatment Of Adults Intermediate And High Risk Myelofibrosis With Low Platelet Count. Journal of Pharmaceutical Negative Results 2023, 649-652. https://doi.org/10.47750/pnr.2023.14.S01.84.